GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • Oxford University Press (OUP)  (66)
  • 1
    In: Age and Ageing, Oxford University Press (OUP), Vol. 51, No. 11 ( 2022-11-02)
    Abstract: The Mobile Health Technology for Improved Screening and Optimized Integrated Care in AF (mAFA-II) randomised trial demonstrated the efficacy of a mobile health (mHealth) technology-implemented ‘Atrial fibrillation Better Care’ (ABC) pathway-approach (mAFA intervention) in reducing the risk of adverse events in patients with atrial fibrillation (AF). Whether these benefits also apply to older patients is unclear. In this ancillary analysis, we evaluated the effect of mAFA intervention among older AF patients. Methods The mAFA-II trial enrolled adult AF patients across 40 centres in China. For this analysis, we defined older patients as those aged ≥75 years. Primary outcome was the composite of ischemic stroke or thromboembolism, all-cause death and rehospitalisation. The effect of mAFA intervention was assessed through multivariable Cox-regression models. We also evaluated the interaction between age and effect of the mAFA intervention in the main trial population. Results In this analysis, we included 1,163 AF patients ≥75 years (mean age: 82.6 ± 5.3 years, 43.1% females); 520 were allocated to mAFA intervention, 643 to usual care. mAFA intervention was associated with a significant reduction of the primary composite outcome (adjusted hazard ratio [aHR]: 0.58, 95% confidence interval [CI] : 0.35–0.97) and rehospitalisations alone (aHR: 0.47, 95%CI: 0.24–0.91). Significant interaction between age and mAFA intervention effect was observed for both the composite outcome (P = 0.002) and rehospitalisation alone (P = 0.015), with the effect decreasing as age increased, particularly among patients ≥80 years old. Conclusions A mHealth technology-implemented ABC pathway is effective in reducing adverse clinical outcomes in older AF patients. The benefits obtained with mAFA intervention were attenuated at extreme ages.
    Type of Medium: Online Resource
    ISSN: 0002-0729 , 1468-2834
    Language: English
    Publisher: Oxford University Press (OUP)
    Publication Date: 2022
    detail.hit.zdb_id: 2065766-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: Nucleic Acids Research, Oxford University Press (OUP), Vol. 46, No. D1 ( 2018-01-04), p. D1217-D1222
    Type of Medium: Online Resource
    ISSN: 0305-1048 , 1362-4962
    RVK:
    Language: English
    Publisher: Oxford University Press (OUP)
    Publication Date: 2018
    detail.hit.zdb_id: 1472175-2
    SSG: 12
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    Online Resource
    Online Resource
    Oxford University Press (OUP) ; 2019
    In:  Nucleic Acids Research Vol. 47, No. D1 ( 2019-01-08), p. D1118-D1127
    In: Nucleic Acids Research, Oxford University Press (OUP), Vol. 47, No. D1 ( 2019-01-08), p. D1118-D1127
    Type of Medium: Online Resource
    ISSN: 0305-1048 , 1362-4962
    RVK:
    Language: English
    Publisher: Oxford University Press (OUP)
    Publication Date: 2019
    detail.hit.zdb_id: 1472175-2
    SSG: 12
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    Online Resource
    Online Resource
    Oxford University Press (OUP) ; 2017
    In:  Bioinformatics Vol. 33, No. 20 ( 2017-10-15), p. 3276-3282
    In: Bioinformatics, Oxford University Press (OUP), Vol. 33, No. 20 ( 2017-10-15), p. 3276-3282
    Abstract: Genetic and gene expression variations within and between populations and across geographical regions have substantial effects on the biological phenotypes, diseases, and therapeutic response. The development of precision medicines can be facilitated by the OMICS studies of the patients of specific ethnicity and geographic region. However, there is an inadequate facility for broadly and conveniently accessing the ethnic and regional specific OMICS data. Results Here, we introduced a new free database, HEROD, a human ethnic and regional specific OMICS database. Its first version contains the gene expression data of 53 070 patients of 169 diseases in seven ethnic populations from 193 cities/regions in 49 nations curated from the Gene Expression Omnibus (GEO), the ArrayExpress Archive of Functional Genomics Data (ArrayExpress), the Cancer Genome Atlas (TCGA) and the International Cancer Genome Consortium (ICGC). Geographic region information of curated patients was mainly manually extracted from referenced publications of each original study. These data can be accessed and downloaded via keyword search, World map search, and menu-bar search of disease name, the international classification of disease code, geographical region, location of sample collection, ethnic population, gender, age, sample source organ, patient type (patient or healthy), sample type (disease or normal tissue) and assay type on the web interface. Availability and implementation The HEROD database is freely accessible at http://bidd2.nus.edu.sg/herod/index.php. The database and web interface are implemented in MySQL, PHP and HTML with all major browsers supported.
    Type of Medium: Online Resource
    ISSN: 1367-4803 , 1367-4811
    Language: English
    Publisher: Oxford University Press (OUP)
    Publication Date: 2017
    detail.hit.zdb_id: 1468345-3
    SSG: 12
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    Online Resource
    Online Resource
    Oxford University Press (OUP) ; 2022
    In:  Neuro-Oncology Vol. 24, No. 6 ( 2022-06-01), p. 903-913
    In: Neuro-Oncology, Oxford University Press (OUP), Vol. 24, No. 6 ( 2022-06-01), p. 903-913
    Abstract: Elucidating the mechanism by which biallelic inactivation evolved could provide a mechanistic understanding for NF2 tumorigenesis and also a rationale for clinical management. Methods A cohort of 60 NF2 patients was recruited. Next-generation sequencing of tumor and paired control samples was used to explore how NF2 mutations evolve in determining the clinical phenotypes. Results In total, 60 blood samples (one from each patient) and 61 (from 35 patients) NF2-associated tumors were collected. Next-generation sequencing of the blood samples detected “first hit” NF2 mutation in 35/60 donors (58.3%), 82.9% of which (29/35) bear heterozygous germline mutations, and 17.1% (6/35) of which are mosaics with variable allelic frequency (VAF). While a number of NF2 patients were found without germline mutation, most (57/61, 93.4%) NF2-associated tumors were identified with NF2 somatic mutation. We calculated the correlation between the onset latency of mosaic and germline NF2 allele carriers with the mosaicism VAF. The mosaicism VAF is negatively and linearly correlated to clinical symptom onset latency (R2 = 0.3677, P = .00351), suggesting biallelic inactivation probability is a linear function of “first hit” prevalence in the body. The second NF2 somatic mutation occurrence time positively correlates with the onset of clinical symptoms (R2 = 0.4151, P = .02633), suggesting tumor growth is linearly proportional to the time after biallelic inactivation. Conclusions Our results suggested that biallelic inactivation of NF2 evolved through neutral drift and preexisting first hit NF2 allele determines certain aspects of the clinical symptoms. Genetic diagnosis should be included in the diagnostic criteria and treatment consideration of NF2.
    Type of Medium: Online Resource
    ISSN: 1522-8517 , 1523-5866
    Language: English
    Publisher: Oxford University Press (OUP)
    Publication Date: 2022
    detail.hit.zdb_id: 2094060-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 6
    Online Resource
    Online Resource
    Oxford University Press (OUP) ; 2016
    In:  Journal of Pharmacy and Pharmacology Vol. 68, No. 8 ( 2016-07-04), p. 980-988
    In: Journal of Pharmacy and Pharmacology, Oxford University Press (OUP), Vol. 68, No. 8 ( 2016-07-04), p. 980-988
    Abstract: We developed Cur nanosuspension (Cur-NS) with PVPK30 and SDS as stabilizers to improve poor water solubility and short biological half-time of Cur. Methods Physicochemical characterization of Cur-NS was characterized systematically. The in-vitro dissolution, cytotoxicity and in-vivo pharmacokinetic experiments of Cur-NS were also evaluated. Key findings Scanning electron microscope indicated that the morphologies of Cur-NS were spherical or ellipsoidal in shape. X-ray diffraction verified that Cur was successfully developed as nanoparticles with an amorphous phase in Cur-NS. Fourier transform infrared spectroscopy suggested there was no degradation about Cur in the Cur-NS. Furthermore, the in-vitro study showed that the cumulative release of the Cur-NS was 82.16 ± 2.62% within 34 h and the cytotoxicity of the Cur-NS against HepG2 cells was much better than raw Cur. Besides, in-vivo pharmacokinetics in rats by intravenous injection displayed that the in-vivo process of Cur-NS pertained to two-compartment model. Meanwhile, the t1/2 and AUC0–t of Cur-NS were enhanced by 11.0-fold and 4.2-fold comparing to Cur solution. Conclusions The Cur-NS significantly increased the water solubility and half-time of Cur, suggesting its potential as a nanocarrier in the delivery of Cur for future clinical application.
    Type of Medium: Online Resource
    ISSN: 2042-7158 , 0022-3573
    Language: English
    Publisher: Oxford University Press (OUP)
    Publication Date: 2016
    detail.hit.zdb_id: 2041988-0
    detail.hit.zdb_id: 2050532-2
    SSG: 15,3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 7
    In: Clinical Infectious Diseases, Oxford University Press (OUP), Vol. 74, No. 11 ( 2022-06-10), p. 1925-1932
    Abstract: Pradefovir is a liver-targeted prodrug of adefovir, a nucleoside/nucleotide analogue with antiviral activity against hepatitis B virus (HBV) DNA polymerase. This phase 2 study compared the efficacy and safety of oral pradefovir (30, 45, 60, or 75 mg) versus tenofovir disoproxil fumarate (TDF; 300 mg) and aimed to identify the most appropriate dose of pradefovir for the forthcoming phase 3 study. Methods Treatment-naive and experienced (not on treatment & gt;6 months) patients with chronic hepatitis B were eligible. Results A total of 240 participants were randomized and treated in the study (48 per group). Approximately 80% were hepatitis B e antigen (HBeAg) positive, and 10% had liver cirrhosis. The reductions from baseline in HBV DNA levels achieved at week 24 were 5.40, 5.34, 5.33, and 5.40 log10 IU/mL, with pradefovir doses of 30-, 45-, 60-, and 75-mg, respectively, compared with 5.12 log10 IU/mL with TDF. However, HBeAg loss was attained by more participants who received 45-, 60-, or 75-mg pradefovir than by those receiving TDF (12%, 6%, and 9% vs 3%). The TDF group exhibited a more significant increase in serum creatinine than the pradefovir 30- and 45-mg groups, and serum phosphate levels were comparable among all groups. Most adverse events (AEs) were mild (grade 1). No treatment-related severe AEs were reported. Overall, AEs and laboratory abnormalities were comparable to those in the TDF group. Conclusions Pradefovir and TDF exhibited comparable reductions in HBV DNA levels. All treatments were safe and well tolerated. Clinical Trials registration NCT00230503 and China Drug Trials CTR2018042
    Type of Medium: Online Resource
    ISSN: 1058-4838 , 1537-6591
    RVK:
    Language: English
    Publisher: Oxford University Press (OUP)
    Publication Date: 2022
    detail.hit.zdb_id: 2002229-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 8
    In: The Journal of Infectious Diseases, Oxford University Press (OUP), Vol. 209, No. 4 ( 2014-2-15), p. 551-556
    Type of Medium: Online Resource
    ISSN: 1537-6613 , 0022-1899
    RVK:
    Language: English
    Publisher: Oxford University Press (OUP)
    Publication Date: 2014
    detail.hit.zdb_id: 1473843-0
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 9
    Online Resource
    Online Resource
    Oxford University Press (OUP) ; 2023
    In:  Nephrology Dialysis Transplantation Vol. 38, No. Supplement_1 ( 2023-06-14)
    In: Nephrology Dialysis Transplantation, Oxford University Press (OUP), Vol. 38, No. Supplement_1 ( 2023-06-14)
    Abstract: Diabetic kidney disease(DKD) has a high prevalence rate and many complications, and it has become the main reason for the progression of chronic kidney disease to end-stage renal disease (ESRD). At present, some clinical biomarkers, such as urinary albumin / creatinine ratio (ACR), serum creatinine and cystatin C, are of positive significance in evaluating the course of DKD, but these indicators are greatly affected by the state of the body itself, which can no longer meet the clinical needs. Decoy receptor 2 (DcR2) is the transmembrane receptor of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and is a biomarker of cell senescence and apoptosis resistance. Our previous study found that the level of urinary DcR2/Cr is closely related to renal function damage and renal interstitial injury. Considering that there is still a lack of research on predicting the poor prognosis of DKD with related biomarkers, this study detected the level of DcR2/Cr in the urine of patients with DKD for the first time to analyze the relationship between the poor prognosis of DKD and to determine whether urinary DcR2/Cr can be used as an index to predict the poor prognosis of DKD. Method A total of 181 inpatients with DKD were collected from the Department of Nephrology of Daping Hospital from 2018 to 2022, of which 121 urine samples were collected. The clinical data of the patients were collected and divided into three quantiles according to the level of urinary DcR2/Cr. Group 1: DcR2/Cr & lt; 321ng / mmol. group 2: 321 ≤ DcR2/Cr ≤ 505ng / mmol. group 3: DcR2/Cr & gt; 505ng / mmol. The adverse prognosis was based on the occurrence of end point events. Multivariate Cox regression analysis was used to evaluate the relationship between urinary DcR2/Cr level and poor prognosis of DKD. ROC curve was used to analyze the value of biomarkers in predicting the poor prognosis of DKD. Results With the increase of urinary DcR2/Cr level, the levels of urinary Microalbumin, ACR, NAG, CYC and serum creatinine increased, while urinary creatinine and eGFR decreased gradually. Correlation analysis showed that the level of DcR2/Cr was positively correlated with ACR, cystatin C and NAG, and negatively correlated with eGFR, while DcR2/Cr was positively correlated with IFTA score, renal artery hyaline change score and renal arteriosclerosis score. Cox regression analysis showed that there was a significant correlation between the level of DcR2/Cr and the occurrence of poor prognosis (corrected by the model), and the risk of poor prognosis in the DcR2/Cr3 group was 9.903 times higher than that in the DcR2/Cr1 group. Kaplan-Meier survival curve showed that the higher the level of DcR2/Cr, the worse the prognosis. ROC curve analysis showed that the area under urinary DcR2 curve was the largest (AUC = 0.811), which was higher than ACR, CYC and SCr, and the best intercept value was 389.0ng/mmol. Conclusion Urinary DcR2/Cr is superior to ACr, Scr, Cyc and other clinical indexes in predicting the poor prognosis of DKD. It is an effective biomarker for predicting poor prognosis of DKD.
    Type of Medium: Online Resource
    ISSN: 0931-0509 , 1460-2385
    Language: English
    Publisher: Oxford University Press (OUP)
    Publication Date: 2023
    detail.hit.zdb_id: 1465709-0
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 10
    Online Resource
    Online Resource
    Oxford University Press (OUP) ; 2023
    In:  Nucleic Acids Research Vol. 51, No. 9 ( 2023-05-22), p. e49-e49
    In: Nucleic Acids Research, Oxford University Press (OUP), Vol. 51, No. 9 ( 2023-05-22), p. e49-e49
    Abstract: Long noncoding RNAs (lncRNAs) are  & gt;200 nt RNA transcripts without protein-coding potential. LncRNAs can be categorized into intergenic, intronic, bidirectional, sense, and antisense lncRNAs based on the genomic localization to nearby protein-coding genes. The current CRISPR-based lncRNA knockout strategy works efficiently for lncRNAs distant from the protein-coding gene, whereas it causes genomic perturbance inevitably due to technical limitations. In this study, we introduce a novel lncRNA knockout strategy, BESST, by deleting the genomic DNA fragment from the branch point to the 3′ splicing site in the last intron of the target lncRNA. The BESST knockout exhibited comparable or superior repressive efficiency to RNA silencing or conventional promoter-exon1 deletion. Significantly, the BESST knockout strategy minimized the intervention of adjacent/overlap protein-coding genes by removing an average of ∼130 bp from genomic DNA. Our data also found that the BESST knockout strategy causes lncRNA nuclear retention, resulting in decapping and deadenylation of the lncRNA poly(A) tail. Further study revealed that PABPN1 is essential for the BESST-mediated decay and subsequent poly(A) deadenylation and decapping. Together, the BESST knockout strategy provides a versatile tool for investigating gene function by generating knockout cells or animals with high specificity and efficiency.
    Type of Medium: Online Resource
    ISSN: 0305-1048 , 1362-4962
    RVK:
    Language: English
    Publisher: Oxford University Press (OUP)
    Publication Date: 2023
    detail.hit.zdb_id: 1472175-2
    SSG: 12
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...